Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenanc...(NS). Building on the science generated f...),Health

Date:12/20/2007

NS). Building on the science generated from the Nobel Prize winning laboratory of Dr. Paul Greengard at The Rockefeller University, the Company develops compounds that have the potential to treat a wide range of diseases associated with the CNS, including schizophrenia, sleep disorders, Parkinson's and Alzheimer's disease, cognitive deficits in schizophrenia, depression, and female sexual dysfunction and other disorders pertaining to Women's Health. To aid in the development process, the Company incorporates its CNSProfile(TM), a state-of-the-art platform that allows ITI to choose compounds with the strongest potential to succeed in these difficult to treat diseases.

Contact:

Intra-Cellular Therapies, Inc. Burns McClellan, Inc.

Allen A. Fienberg, Ph.D Juliane Snowden (Investors)

Vice President, Business Development Kathy L. Nugent, Ph.D. (Media)

212-923-3344 212-213-0006

'/>"/>

SOURCE Intra-Cellular Therapies, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
2. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
3. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
4. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
7. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
8. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
9. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
10. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma